At its first virtual investor event, biotech company Centogene set a bold mission: to cure 100 rare diseases within the next decade. A leader in the field of genetic diagnostics, Centogene used the June 22 event to present its strategic priorities, outlining its plans to speed the discovery…
News
The Foundation for Prader-Willi Research (FPWR) announced its support for ARD-101, an investigational, gut-targeting Prader-Willi syndrome (PWS) therapy, by investing in Aardvark Therapeutics, the treatment’s developer. “FPWR is committed to advancing the development of innovative treatments through multiple channels,” John Walter, CEO of FPWR, said in a…
To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…
People with Prader-Willi syndrome (PWS) are aware of the disease, but not of its social consequences, a small single-site study has found. These findings may have important clinical implications for care as “patients believe they are capable of independent living when they are actually not,” the researchers wrote. The…
Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual Living Rare Living Stronger Patient and Family Forum, hosted by the National Organization for Rare Disorders (NORD) and set this year for June 26-27. The conference brings together patients,…
In adults with Prader-Willi syndrome (PWS), use of growth hormone (GH) treatment may improve the quality of sleep with no significant negative effects on breathing, such as obstructive sleep apnea, a Scandinavian study suggested. The study, “Effects of Growth Hormone treatment on sleep-related parameters in adults with Prader-Willi…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…
The genetic profile of children with Prader-Willi syndrome (PWS) correlates with their age at diagnosis and at the start of growth hormone treatment, as well as with pre-treatment levels of insulin-like growth factor 1 (IGF1) — a hormone that promotes…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will award grants to top advocates of rare disease organizations who participate in the week’s pre-events. The top 50 point-earners will be eligible to win $1,000 to $5,000in grants, totaling up…
Editor’s Note: This is the second of two articles looking at DCCR, Soleno Therapeutics’ investigational treatment, and the DESTINY-PWS trial. The first can be found here. Likely next steps for diazoxide choline controlled release (DCCR) tablets, a potential therapy for Prader-Willi syndrome (PWS), remain to be known,…
Recent Posts
- Setting boundaries at home and work helps me as a PWS caregiver
- FDA lifts hold on clinical testing of experimental PWS treatment
- Redefining the menu to keep the magic of Halloween alive with PWS
- PWS doctors skip sleep studies for early growth hormone therapy
- We all ‘come out’ in our own ways, including PWS families
- Testosterone therapy aids bone health in PWS, with low behavior impact
- Why common illnesses can look different with Prader-Willi syndrome
- Getting away is hard for couples raising a medically complex child
- Interdisciplinary inpatient care may boost outcomes in PWS patients
- Staying present is a challenge when you know what PWS might bring next